Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date β because we believe great analysis should be held accountable.
The AI Optics Value Chain: From Switch Silicon to Optical Engines
AI clusters are becoming optical systems as much as compute systems. The visible winner is still the GPU, but the hidden constraint is increasingly the network: switch radix, SerDes speed, optical-port density, power per bit, fiber management, and the ability to move from 800G to 1.6T without letting the interconnect budget explode.
The AI Halo Effect vs. The Dark Pool Reality: Why Monolithic Power Systems is Running on Fumes
MPWR stock surged on AI hype, but executives are massively selling shares. Passive index funds are buying, providing exit liquidity. Hidden market data reveals institutional selling.
The Semiconductor Mirage: Why ASE Technology's 250% Run is a Gamma-Fueled Trap
ASE Technology's 250% surge is a gamma squeeze, not fundamental growth. Options activity and dark pool data show a synthetic rally, signaling an imminent sharp reversal.
The Anatomy of a Shakeout: The Generational Mispricing of Caris Life Sciences
Caris Life Sciences' stock plunged despite stellar earnings and a $1.2B credit facility. This appears to be a manufactured shakeout, as data shows institutions likely engineering panic to accumulate shares at a generational discount.
The YUTREPIA Money Printer: Why Liquidia's 25% Breakout is Just the First Inning
Liquidia's 25% breakout is just the start. Q1 2026 shows YUTREIA's $130M sales turned it into a cash-minting machine. Strong institutional buying signals a major structural repricing, not a peak.
The Alchemy of Abivax: Why Wall Street's Hidden Prints Reveal a Biotech Powder Keg
Abivax is restructuring its balance sheet, buying back royalties with minimal dilution. Its large cash runway and stealth institutional accumulation signal strong potential ahead of key clinical milestones.
The AI Glass Delusion: Unpacking Corningβs $177 Billion Mirage
Corning's AI-driven stock surge to $177B is a mirage. The NVIDIA deal dilutes shareholders and requires massive capital spending. Insiders are selling, not buying, the hype.
The Anatomy of a Squeeze: Why ZBIO is the Market's Best Kept Secret
ZBIO's recent capital raise funds its key drug launch. Insiders are heavily buying, signaling strong conviction ahead of an imminent FDA submission, while the stock remains undervalued.
The Dark Pool Anatomy of Krystal Biotechβs Breakout
Krystal Biotech's breakout to $286.95 was driven by institutional dark pool activity, not just strong Q1 2026 earnings. Analysis of off-exchange data reveals a setup of extreme shorting preceding the engineered price move.
The ORKA Liquidity Trap: When "Cures" Are Used to Cash Out
ORKA's positive trial data triggered a retail surge, but management immediately sold $700M in new shares, causing the stock to plummet. Insiders sold, revealing the data as a liquidity event for a major dilution.
The Anatomy of a Collapse: Decoding POET's 47% Plunge
POET stock plunged 47% after Marvell canceled orders due to POET's confidentiality breach. Options and dark pool data showed institutional investors likely had advance knowledge and were shorting before the public announcement.
The Asymmetric Trap Hidden in Mirum Pharmaceuticals (MIRM)
Mirum Pharma (MIRM) shows explosive revenue growth and strong cash, yet has 20% short interest. Major funds are accumulating while retail bets on puts, creating a high-tension setup ahead of key positive trial data.
The AI Mirage: Why AXTI's 400% Melt-Up is a Ticking Time Bomb
AXTI's 400% AI-driven surge masks unprofitability. Insiders dumped millions in shares as retail bought the narrative, signaling a dangerous disconnect from fundamentals.
The Anatomy of a Stealth Squeeze: Why Acrivon Therapeutics is Smart Money's Best Kept Secret
Acrivon Therapeutics is a biotech stock showing signs of a major institutional accumulation phase, with management's strategic moves and hidden market data pointing to an imminent, powerful price surge.
The Shadow Accumulation of Prelude Therapeutics: Why The Obvious Dilution is a Trap
Institutional investors, not retail, drove Prelude's recent stock offering. Major funds like OrbiMed increased their stakes, signaling strong confidence in upcoming clinical catalysts despite the apparent dilution.
The Biotech Anomaly: Why the Street is Dead Wrong on ACADIA Pharmaceuticals
ACADIA's stock fell despite strong 2025 earnings, $391M net income, and a $1.28B 2026 outlook. Major funds are accumulating shares, and recent trading data signals a powerful reversal is underway.
The Anatomy of a Biotech Shakeout: Why CytomXβs Post-Offering Bleed is a Dark Pool Mirage
CytomX's post-offering stock drop hides major institutional buying in dark pools, signaling a bullish accumulation phase, not a sell-off.
The Invisible Hand Strangling ZYME's Shorts: A Deep Dive into Biotech's Quietest Squeeze
ZYME's stock surge is driven by a hidden institutional squeeze, not just positive news. Data shows massive off-exchange buying overpowering short sellers, forcing a capitulation.
The Anatomy of a Stealth Squeeze: What the Dark Pools Are Screaming About ARTV
Dark pool data suggests ARTV's surge is a smart money-driven repricing, not irrational. Insiders swapped options for stock before a pivotal autoimmune therapy pivot, signaling major upside.
The $2.25 Billion "Sell The News" Illusion: What Dark Pools Are Hiding in Arbutus Biopharma
Despite a post-settlement price drop, dark pool data reveals aggressive institutional accumulation in Arbutus Biopharma, not selling.